Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Malarikova D, Jorda R, Kupcova K, Senavova J, Dolnikova A, Pokorna E, Kazantsev D, Nozickova K, Sovilj D, Bellanger C, Chiron D, Andera L, Krystof V, Strnad M, Helman K, Klanova M, Trneny M, Havranek O, Klener P.
Malarikova D, et al. Among authors: klener p.
Exp Hematol Oncol. 2024 Mar 25;13(1):34. doi: 10.1186/s40164-024-00499-2.
Exp Hematol Oncol. 2024.
PMID: 38528594
Free PMC article.